CN112654627A - 杂环化合物 - Google Patents

杂环化合物 Download PDF

Info

Publication number
CN112654627A
CN112654627A CN201980058108.7A CN201980058108A CN112654627A CN 112654627 A CN112654627 A CN 112654627A CN 201980058108 A CN201980058108 A CN 201980058108A CN 112654627 A CN112654627 A CN 112654627A
Authority
CN
China
Prior art keywords
compound
ring
group
optionally substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980058108.7A
Other languages
English (en)
Chinese (zh)
Inventor
大达一弘
藤森悠介
牧田直也
古关教孝
林秀树
坂元裕树
峰野胡桃
多贺亮介
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN112654627A publication Critical patent/CN112654627A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201980058108.7A 2018-09-07 2019-09-06 杂环化合物 Pending CN112654627A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-167488 2018-09-07
JP2018167488 2018-09-07
PCT/JP2019/035233 WO2020050409A1 (en) 2018-09-07 2019-09-06 Heterocyclic compound

Publications (1)

Publication Number Publication Date
CN112654627A true CN112654627A (zh) 2021-04-13

Family

ID=68063002

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980058108.7A Pending CN112654627A (zh) 2018-09-07 2019-09-06 杂环化合物

Country Status (12)

Country Link
US (2) US11932657B2 (https=)
EP (1) EP3847176A1 (https=)
JP (1) JP7448527B2 (https=)
KR (1) KR102810086B1 (https=)
CN (1) CN112654627A (https=)
AU (2) AU2019335968B2 (https=)
CA (1) CA3109610A1 (https=)
EA (1) EA202190654A1 (https=)
IL (1) IL280821B2 (https=)
SG (1) SG11202101963XA (https=)
TW (1) TWI854995B (https=)
WO (1) WO2020050409A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115215720A (zh) * 2021-04-19 2022-10-21 中国科学院化学研究所 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用
WO2022228399A1 (zh) * 2021-04-27 2022-11-03 山东轩竹医药科技有限公司 三并环类usp1抑制剂及其用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7448527B2 (ja) 2018-09-07 2024-03-12 大塚製薬株式会社 ヘテロ環式化合物
IL291322B2 (en) 2019-12-09 2026-02-01 Otsuka Pharma Co Ltd Acrylamide compounds
US20230279000A1 (en) 2020-02-26 2023-09-07 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
KR20240054994A (ko) * 2021-09-02 2024-04-26 재규어 테라퓨틱스 피티이 리미티드 AhR 시그널링의 조절에 유용한 화합물
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
JP7527515B1 (ja) * 2022-10-29 2024-08-02 松本油脂製薬株式会社 弾性繊維用処理剤及びその利用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CN103313989B (zh) 2010-12-16 2016-05-04 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
DK3312270T3 (da) 2015-06-16 2020-10-12 Univ Kyoto Fremgangsmåde til fremstilling af plader med høj ydeevne
WO2018195397A2 (en) * 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
WO2019167973A1 (en) 2018-03-01 2019-09-06 Kyoto University Cell cycle progression inhibitor
JP7448527B2 (ja) 2018-09-07 2024-03-12 大塚製薬株式会社 ヘテロ環式化合物
IL291322B2 (en) 2019-12-09 2026-02-01 Otsuka Pharma Co Ltd Acrylamide compounds
JP2022188761A (ja) 2021-06-09 2022-12-21 大塚製薬株式会社 窒素原子含有複素環化合物を用いる血小板産生方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115215720A (zh) * 2021-04-19 2022-10-21 中国科学院化学研究所 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用
CN115215720B (zh) * 2021-04-19 2023-08-22 中国科学院化学研究所 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用
WO2022228399A1 (zh) * 2021-04-27 2022-11-03 山东轩竹医药科技有限公司 三并环类usp1抑制剂及其用途
CN117355532A (zh) * 2021-04-27 2024-01-05 山东轩竹医药科技有限公司 三并环类usp1抑制剂及其用途

Also Published As

Publication number Publication date
AU2019335968A1 (en) 2021-05-06
US20210340157A1 (en) 2021-11-04
WO2020050409A1 (en) 2020-03-12
CA3109610A1 (en) 2020-03-12
IL280821B1 (en) 2024-10-01
EA202190654A1 (ru) 2021-05-27
KR102810086B1 (ko) 2025-05-21
IL280821B2 (en) 2025-02-01
US11932657B2 (en) 2024-03-19
SG11202101963XA (en) 2021-03-30
NZ774547A (en) 2025-10-31
EP3847176A1 (en) 2021-07-14
US20240208999A1 (en) 2024-06-27
TW202035423A (zh) 2020-10-01
JP7448527B2 (ja) 2024-03-12
TWI854995B (zh) 2024-09-11
JP2021536482A (ja) 2021-12-27
AU2024203760A1 (en) 2024-06-20
KR20210056373A (ko) 2021-05-18
IL280821A (en) 2021-04-29
AU2019335968B2 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
CN112654627A (zh) 杂环化合物
JP5159305B2 (ja) チエノトリアゾロジアゼピン化合物及びその医薬としての用途
CN107231802B (zh) 杂环衍生物及其用途
CN112424200B (zh) 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途
RU2681849C2 (ru) Гетероциклические производные и их применение
WO2015057963A1 (en) Fgfr4 inhibitors
JP2010111624A (ja) Ttk阻害作用を有するインダゾール誘導体
TWI836960B (zh) 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN111566100B (zh) 嘧啶类化合物、其制备方法及其医药用途
KR20120034607A (ko) 이미다조〔2,1-b〕〔1,3,4〕티아디아졸 유도체
JP2006515596A (ja) Pparデルタ活性化化合物として用いられるインドールフェニルスルホンアミド誘導体
CN120917003A (zh) 酰基磺酰胺kat6a抑制剂
CN110156656A (zh) 五元杂芳环衍生物、其制备方法、药物组合物及应用
WO2021228215A1 (zh) 可用作RORγ调节剂的联芳基类化合物
HK40048052A (zh) 杂环化合物
JP7657800B2 (ja) アクリルアミド化合物
CN115785154A (zh) 杂芳环化合物及其医药用途
JP2022188761A (ja) 窒素原子含有複素環化合物を用いる血小板産生方法
KR102954013B1 (ko) 브로모도메인 단백질 억제제로서의 설폭시민 화합물과 약학적 조성물 및 이의 의학적 용도
HK40059281A (en) BIARYL COMPOUNDS USEFUL AS RORγMODULATORS
EA046483B1 (ru) Гетероциклическое соединение
HK40068949A (en) Acrylamide compounds
CN105263926A (zh) 苯并噻吩化合物
HK40044332B (en) Sulfoximine compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40048052

Country of ref document: HK